Statistics from Altmetric.com
Probiotics are widely consumed and the widespread advertising is often not really justified by the evidence. Many products were never studied as such and some companies use studies performed with other (and different) products for advertising even during medical conventions. Evidence of benefit is still patchy and the clinician has to take into account the variability of the strains, the doses, the quality of the trials and clinical relevance of end points.
In this issue of Gut, Mohayyedi and colleagues (see page 325) have made an interesting systematic analysis on the randomised controlled trials testing various probiotics in patients with irritable bowel syndrome (IBS).1 They show that many trials are of good quality, that positive results were obtained with some strains, or products combining several strains, but also that studies are heterogeneous and that funnel plot asymmetry suggests biases in the publications (ie, there are more reports on the positive studies than of the negative ones). I agree with the authors that meta-analysis is not wise as the active ingredients and mechanisms of action of various probiotics are very likely to …
Linked articles 167270.
Competing interests Philippe Marteau has received consultancy fees and invitations to speak at conventions by Danone, Nestlé, Biocodex, Merck Médication familiale, Rosel Lallemand, and PiLeJe.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.